Emerging evidence for adapting radiotherapy to immunotherapy
L Galluzzi, MJ Aryankalayil, CN Coleman… - Nature reviews Clinical …, 2023 - nature.com
Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …
infrequently associated with durable objective responses when used as a standalone …
Therapeutic landscape and future direction of metastatic colorectal cancer
H Bando, A Ohtsu, T Yoshino - Nature Reviews Gastroenterology & …, 2023 - nature.com
In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous …
JD Schoenfeld, A Giobbie-Hurder… - The Lancet …, 2022 - thelancet.com
Background Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and
PD-L1 (PD [L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …
PD-L1 (PD [L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …
Radiation therapy-induced remodeling of the tumor immune microenvironment
M Charpentier, S Spada, SJ Van Nest… - Seminars in Cancer …, 2022 - Elsevier
The tumor immune microenvironment is a determinant of response to cancer
immunotherapy and, in many cases, is prognostic for patient survival independently of the …
immunotherapy and, in many cases, is prognostic for patient survival independently of the …
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
AM Monjazeb, ME Daly, G Luxardi, E Maverakis… - Nature …, 2023 - nature.com
Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-
early-stage non-small cell lung cancer (NSCLC). One third of patients progress and …
early-stage non-small cell lung cancer (NSCLC). One third of patients progress and …
[HTML][HTML] Cancer Focus: Radiotherapy and immunology
The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …
delivered with curative intent for local tumor control or as part of a multimodality regimen …
Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application
F Ghiringhelli, C Rébé - Immunological Reviews, 2024 - Wiley Online Library
Even though the discovery of immune checkpoint inhibitors (ICIs) has revolutionized cancer
treatment, a high proportion of patients do not respond. Moreover, some types of cancers are …
treatment, a high proportion of patients do not respond. Moreover, some types of cancers are …
[HTML][HTML] Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
S Al Bitar, M El-Sabban, S Doughan… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
KX Lin, AC Istl, D Quan, A Skaro, E Tang… - Cancer Immunology …, 2023 - Springer
Colorectal cancer (CRC) is the second most common cause of cancer mortality, with
mismatch repair proficient (pMMR) and/or microsatellite stable (MSS) CRC making up more …
mismatch repair proficient (pMMR) and/or microsatellite stable (MSS) CRC making up more …
Oligometastases: emerging evidence
The hypothesis that ablative therapies (such as surgery or radiation) can be used to cure
patients with a limited number of metastases was influential in changing practice. Early …
patients with a limited number of metastases was influential in changing practice. Early …